Michael L. Jones

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

M. Vieth, R. Campbell, B. Anderson, 2003, Journal of medicinal chemistry.

INHIBITORS OF DIHYDROFOLATE REDUCTASE : DESIGN, SYNTHESIS AND ANTIMICROBIAL ACTIVITIES OF 2,4-DIAMINO-6-METHYL-5-ETHYNYLPYRIMIDINES

L. Kuyper, D. Baccanari, S. K. Rudolph, 1999 .

High-Affinity Inhibitors of Dihydrofolate Reductase: Antimicrobial and Anticancer Activities of 7,8-Dialkyl-1,3-diaminopyrrolo(3,2-f) quinazolines with Small Molecular Size.

L. Kuyper, D. Baccanari, H. Friedman, 1996 .

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.

T. Petrova, J. Sredy, D. Sawicki, 2005, Journal of medicinal chemistry.

Reactions of azodiones with electron-rich alkenes. 1,2,4-Triazoline-3,5-diones and vinyl ethers

Michael L. Jones, J. H. Hall, 1983 .

Indanylidenes. 2. Design and synthesis of (E)-2-(4-chloro-6-fluoro-1-indanylidene)-N-methylacetamide, a potent antiinflammatory and analgesic agent without centrally acting muscle relaxant activity.

B. Cooper, G. Rigdon, Michael L. Jones, 2003, Journal of medicinal chemistry.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

S. A. Watkins, H. Brooks, J. Yingling, 2005, Biochemistry.

High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.

L. Kuyper, D. Baccanari, H. Friedman, 1996, Journal of medicinal chemistry.